Uveitis is a collection of inflammatory diseases of the eye. Uncontrolled inflammation can result in long-term vision loss. Adalimumab is a popular anti-inflammatory medication for patients with non-infectious uveitis. At present, there is no standardized dose. It is commonly used once every two weeks. However, we found that patients were still inflamed on this dosing schedule. Therefore, we investigate the effectiveness of once a week dosing for patients who failed twice a week dosing. We hypothesize that once a week dosing is more effective. Through our research, we hope to change practice patterns in order to better serve patients and to reduce the risk of vision loss.
|Effective start/end date||7/1/19 → 6/30/20|
- Illinois Society for the Prevention of Blindness (Award Letter 6/7/19)